Company Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States.
The company offers CAPLYTA for the treatment of schizophrenia in adults.
It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders.
In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety.
Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
| Country | United States |
| IPO Date | Jan 7, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 610 |
| CEO | Dr. Sharon Mates Ph.D. |
Contact Details
Address: 430 East 29th Street New York, New York United States | |
| Website | https://www.intracellulartherapies.com |
Stock Details
| Ticker Symbol | ITCI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001567514 |
| CUSIP Number | 46116X101 |
| ISIN Number | US46116X1019 |
| Employer ID | 36-4742850 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sharon Mates Ph.D. | Co-Founder, Chairman & Chief Executive Officer |
| Sanjeev Narula | Executive Vice President & Chief Financial Officer |
| Dr. Michael Olchaskey | Senior Vice President & Head of Regulatory Affairs |
| Dr. Robert E. Davis Ph.D. | Senior Vice President & Chief Scientific Officer |
| Dr. Suresh K. Durgam M.D. | Executive Vice President & Chief Medical Officer |
| John P. Condon | Senior Vice President, General Counsel & Secretary |
| Juan Fernando Sanchez M.D. | Vice President of Corporate Communications & Investor Relations |
| Karen Patruno Sheehy Esq. | Senior Vice President & Chief Compliance Officer |
| Mark Neumann | EVice President & Chief Commercial Officer |
| Michael I. Halstead J.D. | President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 06, 2024 | 4 | Filing |
| Dec 03, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 4 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 05, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 24, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 15, 2024 | 4 | Filing |